The Exchange Pulse Report published by Express Scripts predicts that compared with 2014, the year 2015 will see a greater number of younger enrollees signing up on healthcare exchanges, which could potentially drive down drug costs for specialty medications.
The Exchange Pulse Report published by Express Scripts predicts that compared with 2014, the year 2015 will see a greater number of younger enrollees signing up on healthcare exchanges, which could potentially drive down drug costs for specialty medications.
Despite this prediction on drug spending, the report found that specialty drug spending in the exchanges increased by 8% over a year: from 34% in the first quarter (Q1) of last year to 42% during Q1 of the current year. Infectious disease, particularly HIV and Hepatitis C, constituted 21% of the pharmacy spend, with HIV being 53% of the specialty claims. The hepatitis C drugs Harvoni (6.4%) and Sovaldi (3.4%) topped the charts for total pharmacy spend, and were followed by the anti-inflammatory antibody Humira (3.2%).
A particular statistic on the report needs attention: only 5% of health exchange members are responsible for 68% of total pharmacy spend, attributable to their use of high-cost medications. While medication non-adherence was higher on the exchanges compared with health plans, individuals on antidepressants fared worse with medication adherence, while hepatitis C patients did better.
The average age of the exchange enrollee has dropped by nearly 4 years, the report states, from 44.5 in Q1 of 2014, to 40.7 years in Q1 of 2015. Significantly, the number of enrollees with drug claims, and particularly specialty claims, reduced significantly between the 2 quarters being compared. The most expensive conditions treated were diabetes, HIV, and inflammatory conditions in Q1 of 2014; this year, hepatitis C replaced inflammatory conditions.
A point to note: families on exchanges, on average, earn $7260 less than families enrolled with health plans.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More